98%
921
2 minutes
20
Influenza virus genome encapsidation is essential for the formation of a helical viral ribonucleoprotein (vRNP) complex composed of nucleoproteins (NP), the trimeric polymerase, and the viral genome. Although low-resolution vRNP structures are available, it remains unclear how the viral RNA is encapsidated and how NPs assemble into the helical filament specific of influenza vRNPs. In this study, we established a biological tool, the RNP-like particles assembled from recombinant influenza A virus NP and synthetic RNA, and we present the first subnanometric cryo-electron microscopy structure of the helical NP-RNA complex (8.7 to 5.3 Å). The helical RNP-like structure reveals a parallel double-stranded conformation, allowing the visualization of NP-NP and NP-RNA interactions. The RNA, located at the interface of neighboring NP protomers, interacts with conserved residues previously described as essential for the NP-RNA interaction. The NP undergoes conformational changes to enable RNA binding and helix formation. Together, our findings provide relevant insights for understanding the mechanism for influenza genome encapsidation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10848707 | PMC |
http://dx.doi.org/10.1126/sciadv.adj9974 | DOI Listing |
Unlabelled: Human noroviruses ( s) are the leading cause of viral gastroenteritis with ≥80% of infections caused by the GII genogroup. HuNoVs are non-enveloped, with an icosahedral capsid composed of 90 dimers of the major capsid protein VP1, which encloses a minor structural protein, VP2, and a VPg-linked positive sense ssRNA genome. Although the atomic structure of the icosahedral capsid formed by VP1 is well characterized using crystallography and cryo-electron microscopy analyses of HuNoV virus-like particles (VLPs), the structures and the localization of VP2 and VPg inside the capsid, how they are incorporated into the capsid, and whether this process requires interactions between them remain unresolved.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Program in Molecular and Cellular Oncogenesis, The Wistar Institute;
Kaposi's sarcoma-associated herpesvirus (KSHV), a gammaherpesvirus implicated in multiple human malignancies, can undergo lytic replication during primary infection, a process that contributes to viral dissemination, immune evasion, and disease pathogenesis. However, the lack of robust in vitro systems for de novo lytic infection has limited insights into early infection events. Here, we present a tractable protocol that employs human colorectal cancer HCT 116 cells as targets for infection with cell-free virions derived from KSHV bacterial artificial chromosome 16 (BAC16)-reactivated iSLK producer cells.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Viral epigenetic modification is an emerging field. As an obligate intracellular parasite, viral genetic material is exposed to host RNA-modifying enzymes. Currently, more than 180 types of RNA modifications have been identified.
View Article and Find Full Text PDFNat Biomed Eng
August 2025
Department of Biomedical Engineering, Columbia University, New York, NY, USA.
The ability of bacteria and viruses to selectively replicate in tumours has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy whereby Salmonella typhimurium bacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. 'Encapsidated' by bacteria, the viral genome can further bypass circulating antiviral antibodies to reach the tumour and initiate replication and spread within immune mice.
View Article and Find Full Text PDFVaccines (Basel)
July 2025
Biopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Rondebosch, Cape Town 7701, South Africa.
Background/objectives: Beak and feather disease virus (BFDV) is the causative agent of psittacine beak and feather disease (PBFD), affecting psittacine birds. There is currently no commercial vaccine or treatment for this disease. This study developed a novel BFDV coat protein mRNA vaccine encapsidated by TMV coat protein to form pseudovirions (PsVs) and tested its immunogenicity alongside BFDV coat protein (CP) subunit and DNA vaccine candidates.
View Article and Find Full Text PDF